Rawia Mohamed: The association between lack of response in an MSI-H patient and heterogeneous MMR status
Rawia Mohamed, Head of the Anatomical Pathology Department at Burjeel Medical City and an Associate Professor at Khalifa University, shared a post on LinkedIn:
“This slide, presented at the GI Oncology Summit by Dr. Rawia Mohamed, highlights the association between lack of response in an MSI-H (microsatellite instability-high) patient and heterogeneous MMR (mismatch repair) status.
The waterfall plot on the slide illustrates tumor response in enrolled patients categorized by MSI and EBV (Epstein-Barr Virus) status, with MSI-H tumors shown in red, EBV-positive tumors in blue, and MSS/EBV-negative tumors in yellow.
A marked patient in the MSI-H category shows minimal or no response to treatment, suggesting that despite the expected sensitivity of MSI-H tumors to immunotherapy, some cases exhibit resistance. This resistance is linked to MMR heterogeneity, as shown in the H&E-stained tissue section and Pentaplex molecular analysis on the right side of the slide.
The findings emphasize that MMR variability within tumors may contribute to treatment resistance, reinforcing the need for deeper molecular profiling to predict therapy outcomes more accurately.
This insight is crucial for developing personalized treatment strategies in GI oncology, ensuring that patients with heterogeneous MMR status receive tailored therapeutic approaches.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023